Skip to main content
Journal cover image

A comparison of antiangiogenic therapies for the prevention of liver metastases.

Publication ,  Journal Article
Mi, J; Sarraf-Yazdi, S; Zhang, X; Cao, Y; Dewhirst, MW; Kontos, CD; Li, C-Y; Clary, BM
Published in: J Surg Res
March 2006

Angiogenesis is essential for solid tumor growth. Although successful antiangiogenic therapies have been demonstrated in animal models, a systematic comparison of the efficacy of different antiangiogenic factors has not been described in the hepatic environment. To address this issue, CT26 murine colon carcinoma cells were transfected with retroviral vectors encoding murine endostatin (mEndostatin), human angiostatin (hAngiostatin), murine-soluble vascular endothelial growth factor receptor-2, (msFlk-1), or murine-soluble Tie2 (msTie2). The transfected cells were then subjected to another round of transfection with a luciferase cDNA-encoding retroviral vector. Expression of these putative antiangiogenic proteins inhibited the proliferation of human umbilical vein endothelial cells in vitro but not tumor cells. To examine effects on tumor growth in vivo, modified cells were delivered via intrasplenic injection into BALB/c mice to induce liver metastases. Tumor burden was measured weekly by bioluminescence. Growth of hepatic metastases in vivo was significantly reduced in mice that were administered cells expressing msTie2 (76% reduction compared with control cells 21 days after intrasplenic inoculation; P < 0.05). Similar results were observed with cells that expressed msFlk-1 and hAngiostatin. However, expression of mEndostatin had no significant effect on the growth of liver metastases compared with control animals. These findings indicate that multiple antiangiogenic pathways are necessary for the growth of hepatic metastases, and each of these pathways is a potential clinically relevant antiangiogenic target for the treatment of this disease.

Duke Scholars

Published In

J Surg Res

DOI

ISSN

0022-4804

Publication Date

March 2006

Volume

131

Issue

1

Start / End Page

97 / 104

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-2
  • Tumor Cells, Cultured
  • Transfection
  • Surgery
  • Receptor, TIE-2
  • Neovascularization, Pathologic
  • Neoplasms, Experimental
  • Mice, Inbred BALB C
  • Mice
  • Liver Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mi, J., Sarraf-Yazdi, S., Zhang, X., Cao, Y., Dewhirst, M. W., Kontos, C. D., … Clary, B. M. (2006). A comparison of antiangiogenic therapies for the prevention of liver metastases. J Surg Res, 131(1), 97–104. https://doi.org/10.1016/j.jss.2005.09.008
Mi, Jing, Shiva Sarraf-Yazdi, Xiuwu Zhang, Yiting Cao, Mark W. Dewhirst, Christopher D. Kontos, Chuan-Yuan Li, and Bryan M. Clary. “A comparison of antiangiogenic therapies for the prevention of liver metastases.J Surg Res 131, no. 1 (March 2006): 97–104. https://doi.org/10.1016/j.jss.2005.09.008.
Mi J, Sarraf-Yazdi S, Zhang X, Cao Y, Dewhirst MW, Kontos CD, et al. A comparison of antiangiogenic therapies for the prevention of liver metastases. J Surg Res. 2006 Mar;131(1):97–104.
Mi, Jing, et al. “A comparison of antiangiogenic therapies for the prevention of liver metastases.J Surg Res, vol. 131, no. 1, Mar. 2006, pp. 97–104. Pubmed, doi:10.1016/j.jss.2005.09.008.
Mi J, Sarraf-Yazdi S, Zhang X, Cao Y, Dewhirst MW, Kontos CD, Li C-Y, Clary BM. A comparison of antiangiogenic therapies for the prevention of liver metastases. J Surg Res. 2006 Mar;131(1):97–104.
Journal cover image

Published In

J Surg Res

DOI

ISSN

0022-4804

Publication Date

March 2006

Volume

131

Issue

1

Start / End Page

97 / 104

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor Receptor-2
  • Tumor Cells, Cultured
  • Transfection
  • Surgery
  • Receptor, TIE-2
  • Neovascularization, Pathologic
  • Neoplasms, Experimental
  • Mice, Inbred BALB C
  • Mice
  • Liver Neoplasms